Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Highlights • Nivolumab is an adjuvant treatment for patients with high-risk resected melanoma. • This indirect treatment comparison (ITC) compared adjuvant nivolumab with placebo. • Placebo was the proxy for a watch-and-wait strategy. • Data used in the ITC were from two phase III trials. • Adjuvant nivolumab improved efficacy versus placebo in high-risk resected melanoma.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
